Introduction
Survival and life expectancy of children with congenital heart defects have dramatically increased in recent years due to advances in medical and surgical management strategies. Children with congenital heart disease (CHD) are at increased risk of neurodevelopmental deficits [1] , and the presence of sensorineural hearing loss (SNHL) may further lead to poor language skills acquisition and speech delays [2] . The prevalence of SNHL in the general pediatric population is estimated to be 0.2% at birth to 0.35% during adolescence [3] . Many studies have estimated the prevalence of SNHL in the premature neonate population and have identified several associated risk factors [4] . One such study estimated the prevalence in neonates to be as high as 13 .7% [5] . Very few studies, however, have attempted to estimate the prevalence of SNHL in children who have undergone congenital heart surgery. Of these studies, one old study estimated the prevalence to be 16% in CHD patients [6] , and a recent study estimated the prevalence to be as high as 28.6% among childhood survivors after the Norwood/Sano operation only [7] . Currently, no clear recommendations exist for audiology screening in patients undergoing repair or palliation of CHD. The American Heart Association recommends audiology examination if there is no audiology examination since birth and if there is any suspicion of hearing impairment after cardiac surgery [8] .
The first purpose of this study was to estimate the prevalence of SNHL in children who underwent congenital heart surgery in our institution and were followed up in our high-risk pediatric cardiology clinics for four years, from 2009 to 2013. The prevalence of SNHL in singleventricle (SV) patients was also compared to that in biventricular (BiV) patients. Another objective of this study was to identify all possible risk factors associated with SNHL in palliated CHD patients to assess the need for routine hearing screening in patients with complex CHD.
Materials And Methods
We performed a retrospective chart review of patients followed in our high-risk pediatric cardiology clinics from 2009 to 2013 who had routine audiology evaluations. The study design was approved by the institutional review board. Data were collected on patient demographics and preoperative variables such as prematurity and birth weight, presence of genetic syndromes, as well as surgical variables such as total cardiopulmonary bypass time, circulatory arrest time, and cross-clamp time ( Table 1) . Post-operative variables were also collected. These included lowest arterial P H . and PaO2, exposure to known ototoxic medications such as furosemide, hydrochlorothiazide, gentamycin, and vancomycin and their cumulative doses in mg/kg along with duration, inotropic scores in the first two postoperative days, need for extracorporeal membrane oxygenation (ECMO), and clinical seizures. Data collection was performed by a research assistant who was blinded to the hearing test results. Table 2 shows various diagnoses in the study patients. Exclusion criteria were any known genetic syndrome association with SNHL or family history of hearing loss, and any previously documented failed newborn screening. Drug dosages were calculated as cumulative doses in mg/kg based on the weight at the time of each operation. Audiology assessment was performed by an experienced pediatric audiologist using ageappropriate and standard procedures. Young children and developmentally delayed children underwent visually reinforced audiometry, while older children underwent behavioral audiological assessment using pure tone audiometry. All children with test results indicating impaired hearing underwent auditory brain stem response for confirmation. Hearing loss was classified as mild when the hearing loss range in decibels (dB) was 26-40 db. Hearing loss range in dB > 40 dB was grouped as moderate to severe to profound loss [9] . Comparisons between normal and abnormal hearing groups were done using the t test. All collected data were deidentified and stored in a password-protected computer database. All statistical tests were run using Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL).
Characteristic

Diagnosis
Number of patients
Results
A total of 172 patients were identified, 20 of whom were found to have hearing impairment ranging from mild loss to moderate to severe to profound loss in one or both ears. No patient met the exclusion criteria. The prevalence of SNHL in asymptomatic; palliated/repaired CHD patients followed in our high-risk clinics undergoing routine surveillance was 11.6% (20 with hearing impairment out of 172 patients). The prevalence of SNHL was higher in SV patients (17.2%) compared to BiV patients (14.7%), but there was no statistically significant difference (odds ratio 1.16, confidence interval: 0.45-3) ( Table 3) . Twenty-seven out of 172 patients were eliminated from univariate analysis due to lack of records, as their surgeries were performed in a different institution. A total of 145 patients were reviewed for univariate analysis. Inotropic score in the first 24 hours of postoperative period (p= 0.05), lowest arterial PaO2 (p=0.003), the duration of furosemide drip (p=0), and bolus doses in days (p=0.03) were found to be statistically different between the two groups ( Table 4 ). However, using logistic regression, we identified no statistically significant predictors for hearing loss. 
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Highlighted items with p-value less than 0.1 were included in the logistic regression. 
Discussion
In our high-risk cohort, we estimated the prevalence of hearing loss of 11.6%, which is higher than in the general pediatric population as well as in neonatal intensive care unit (NICU) survivors (2%-4%) [10] . Limitations of the study include the small population size and the deficiency that not all patients underwent elective screening after congenital heart surgery.
Only those patients followed up in high-risk pediatric cardiology clinics underwent the hearing test. Hence a true prevalence is not possible to calculate from the study. However, the study provides an estimate of prevalence which is higher than the prevalence of SNHL in the general pediatric population. This prevalence study did not examine all possible etiologies of SNHL like cytomegalovirus (CMV) infection, as no serologies were done to test for CMV infection due to this being a retrospective study. The biggest strength of this study is that the exposure to ototoxic medications was compared in the groups. The other advantage of our study is that it included all complexities of CHD, including mild CHD, moderate 2 ventricle, severe 2 ventricle, and palliated single ventricle, and could represent the estimated prevalence in repaired/palliated CHD in general.
Inner ear ischemia and hypo perfusion are the main proven physiological mechanisms for hearing loss after open heart surgery [11] [12] . Hypoxia and bolus administration of furosemide have been reported to be significant risk factors for hearing loss in children after cardiopulmonary bypass surgery [7] . The duration of ECMO therapy and clinical seizure activity prior to ECMO are independently associated with SNHL [13] .
Conclusions
Our study supports the previously proven etiologies of hypoxia and longer duration of furosemide as strongly associated with SNHL. However, using logistic regression, we identified no single independent predictor as statistically significant for causing hearing loss in complex CHD. But because of the high prevalence of SNHL in this group, the results suggest the need for routine audiology screening of all patients with complex CHD, especially in patients who have undergone neonatal cardiac repair as well as palliation below one year of age, irrespective of risk factors. This screening is necessary to identify children at risk and intervene before SNHL negatively affects their neurodevelopment.
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